Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9267934 | Journal of Autoimmunity | 2005 | 8 Pages |
Abstract
Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor:Fc) in a prospective pilot trial. While the plasma anti-acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune complexes, IL-10 and IFN-γ. There was a direct correlation between plasma IL-6, TNF-α and IFN-γ levels and the post-treatment clinical scores of patients. Moreover, patients with lower pre-treatment plasma IL-6 and IFN-γ levels attained better clinical improvement following etanercept treatment.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Erdem Tüzün, Matthew N. Meriggioli, Julie Rowin, Huan Yang, Premkumar Christadoss,